On May 24, 2010 the FDA approved Genzyme’s Lumizyme for the treatment of patients with Pompe disease who are over

CAMBRIDGE, Mass. – Genzyme Corporation (Nasdaq: GENZ) announced today that the FDA has granted U.S. marketing approval for LumizymeTM (alglucosidase

To read a factual account of the true history of Pompe Disease, please visit Pompe Disease—The Real Story.

The AMDA issued a press release regarding the film, Extraordinary Measures. The press release can be found here. In addition,

This information was complied from the information provided on clinicaltrials.gov. To read, please download file by clicking here.